Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Comparison of HIV-, HBV-, HCV- and co-infection prevalence between Chinese and Burmese intravenous drug users of the China-Myanmar border region.

Zhou YH, Liu FL, Yao ZH, Duo L, Li H, Sun Y, Zheng YT.

PLoS One. 2011 Jan 21;6(1):e16349. doi: 10.1371/journal.pone.0016349.

2.
3.

High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China.

Zhou YH, Yao ZH, Liu FL, Li H, Jiang L, Zhu JW, Zheng YT.

PLoS One. 2012;7(8):e42937. doi: 10.1371/journal.pone.0042937. Epub 2012 Aug 16.

4.

Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study.

Dong Y, Qiu C, Xia X, Wang J, Zhang H, Zhang X, Xu J.

Arch Virol. 2015 Apr;160(4):929-36. doi: 10.1007/s00705-014-2311-0. Epub 2015 Jan 24.

PMID:
25616842
5.

Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China.

Chen X, He JM, Ding LS, Zhang GQ, Zou XB, Zheng J.

Arch Virol. 2013 Sep;158(9):1889-94. doi: 10.1007/s00705-013-1681-z. Epub 2013 Apr 4.

PMID:
23553454
6.

Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.

Devi KhS, Brajachand N, Singh HL, Singh YM.

J Commun Dis. 2005 Mar;37(1):73-7.

PMID:
16637404
7.

Study on the blood-borne virus co-infection and T lymphocyte subset among intravenous drug users.

Li JR, Gong RY, Tian KL, Wang J, Wang YX, Huang HJ.

World J Gastroenterol. 2007 Apr 28;13(16):2357-62.

8.

Multiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China's HIV/HCV Epidemics.

Chen M, Ma Y, Chen H, Luo H, Dai J, Song L, Yang C, Mei J, Yang L, Dong L, Jia M, Lu L.

PLoS One. 2015 Nov 12;10(11):e0142543. doi: 10.1371/journal.pone.0142543. eCollection 2015.

9.

Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javan prisons, Indonesia.

Prasetyo AA, Dirgahayu P, Sari Y, Hudiyono H, Kageyama S.

J Infect Dev Ctries. 2013 Jun 15;7(6):453-67. doi: 10.3855/jidc.2965.

10.

Systematic review of HIV and HCV infection among drug users in China.

Bao YP, Liu ZM.

Int J STD AIDS. 2009 Jun;20(6):399-405. doi: 10.1258/ijsa.2008.008362. Review.

PMID:
19451325
11.

HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran.

Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M.

Int J Infect Dis. 2010 Jan;14(1):e28-33. doi: 10.1016/j.ijid.2009.03.002. Epub 2009 May 21.

12.

Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain.

Santana Rodríguez OE, Malé Gil ML, HernándezSantana JF, Limiñana Cañal JM, Martín Sánchez AM.

Eur J Epidemiol. 1998 Sep;14(6):555-61.

PMID:
9794122
13.

Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.

Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M.

BMC Infect Dis. 2006 Jun 8;6:93.

14.

Influence of interleukin 10 polymorphisms -592 and -1082 to the HIV, HBV and HCV serostatus among intravenous drug users.

Kallas E, Huik K, Pauskar M, Jõgeda EL, Karki T, Des Jarlais D, Uusküla A, Avi R, Lutsar I.

Infect Genet Evol. 2015 Mar;30:175-80. doi: 10.1016/j.meegid.2014.12.023. Epub 2014 Dec 24.

PMID:
25542814
15.

Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.

Rai RR, Mathur A, Mathur D, Udawat HP, Nepalia S, Nijhawan S, Mathur A.

Trop Gastroenterol. 2007 Jan-Mar;28(1):19-23.

PMID:
17896605
16.

Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L.

Lancet. 2011 Aug 13;378(9791):571-83. doi: 10.1016/S0140-6736(11)61097-0. Epub 2011 Jul 27. Review.

17.

Prevalence of Hepatitis B virus and/or Hepatitis C virus co-infections in prisoners infected with the Human Immunodeficiency Virus.

Pontali E, Ferrari F.

Int J Prison Health. 2008;4(2):77-82. doi: 10.1080/17449200802038207.

PMID:
18464061
18.

[A study on the prevalence rates of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infections in intravenous drug users].

Wang YC, Xu SH, Li XH, Song AJ, Jia XR, Zhuang H.

Zhonghua Liu Xing Bing Xue Za Zhi. 2006 Sep;27(9):777-9. Chinese.

PMID:
17299963
19.

A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations.

Removille N, Origer A, Couffignal S, Vaillant M, Schmit JC, Lair ML.

BMC Public Health. 2011 May 19;11:351. doi: 10.1186/1471-2458-11-351.

20.

Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia.

Shapatava E, Nelson KE, Tsertsvadze T, del Rio C.

Drug Alcohol Depend. 2006 Apr;82 Suppl 1:S35-8.

PMID:
16769443

Supplemental Content

Support Center